PhaseV is a Boston, MA-based company that specializes in AI/ML-driven clinical development. It provides a vertical AI platform that supports end-to-end clinical development from trial design through execution. The platform comprises four core applications: Trial Optimizer for Bayesian, adaptive, and fixed-trial optimization and implementation; Causal ML for heterogeneous treatment effect estimation to uncover hidden signals and identify high-potential subpopulations and endpoints; and Causal Disease Modeling to inform R&D and life-cycle management. Its Clinical Operations application offers Causal ML-driven site selection, site performance analytics, real-time trial progress monitoring, and integration of virtual control arms. PhaseV has delivered results for more than 30 pharma/biotech sponsors and CROs across therapeutic areas including neurology, oncology, immunology, GI and rare diseases. The company raised $50M in a Series A and plans to use the funds to expand operations and its development efforts; total funding to date is $65M. PhaseV develops causal machine learning technology to optimize clinical trial design and analysis, using proprietary ML to detect hidden signals in clinical data and extract actionable insights. The company provides an ML-driven adaptive process that can accelerate drug development and increase certainty through retrospective analysis and real-time trial adaptation. PhaseV offers two service lines: assessment and implementation of adaptive trial designs, and retrospective analysis to evaluate endpoints and subpopulations and support drug repurposing. Its approach has been applied across therapeutic areas including oncology, endocrinology, autoimmune diseases, and rare diseases. The company is led by CEO Dr. Raviv Pryluk and operates from Tel Aviv, Israel and Boston, MA. It plans to use the newly raised funds to expand operations and further development efforts.

Total raised

$65M

Funding rounds

2

Latest round

Series A

Latest activity

May 2025